Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome

Matrix Biology

Volumn 57-58, Issue , 2017, Pages 45-54

  Cosgrove, Dominic ^a   Liu, Shiguang ^b  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN RECEPTOR; COLLAGEN TYPE 4; ALPHA INTEGRIN; AUTOANTIGEN; COL4A4 PROTEIN, HUMAN; COL4A5 PROTEIN, HUMAN; ITGA8 PROTEIN, HUMAN; PROTEIN BINDING; TYPE IV COLLAGEN ALPHA3 CHAIN;

ALPORT SYNDROME; BIOMECHANICS; DISEASE COURSE; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; KIDNEY INTERSTITIUM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; BASEMENT MEMBRANE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; NEPHRITIS; PATHOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

AUTOANTIGENS; BASEMENT MEMBRANE; COLLAGEN TYPE IV; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHA CHAINS; KIDNEY GLOMERULUS; MUTATION; NEPHRITIS, HEREDITARY; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, COLLAGEN; SIGNAL TRANSDUCTION;

EID: 84994145090     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2016.08.005     Document Type: Review

References (70)

1. [1] Kühn, K., Basement membrane (type IV) collagen. Matrix Biol. 14 (1995), 439–445.
2. [2] Timpl, R., Brown, J.C., Supramolecular assembly of basement membranes. Bioessays 18 (1996), 123–132.
3. [3] Boutaud, A., Borza, D.B., Bondar, O., Gunwar, S., Netzer, K.O., Singh, N., Ninomiya, Y., Sado, Y., Noelken, M.E., Hudson, B.G., Type IV collagen of the glomerular basement membrane. Evidence that the chain specificity of network assembly is encoded by the noncollagenous NC1 domains. J. Biol. Chem. 275 (2000), 30716–30724.
4. [4] Hudson, B.G., The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J. Am. Soc. Nephrol. 15 (2004), 2514–2527.
5. [5] Kang, J.K., Colon, S., Hellmark, T., Sado, Y., Hudson, B.G., Identification of noncollageneous sites encoding specific interactions and quaternary assembly of α3α4α5(IV) collagen. J. Biol. Chem. 283 (2008), 35070–35077.
6. [6] Borza, D.B., Bondar, O., Ninomiya, Y., Sado, Y., Naito, I., Todd, P., Hudson, B.G., The NC1 domain of collagen IV encodes a novel network composed of the alpha 1, alpha 2, alpha 5, and alpha 6 chains in smooth muscle basement membranes. J. Biol. Chem. 276 (2001), 28532–28540.
7. [7] Gunwar, S., Ballester, F., Noelken, M.E., Sado, Y., Ninomiya, Y., Hudson, B.G., Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome. J. Biol. Chem. 273 (1998), 8767–8775.
8. [8] Knebelmann, B., Breillat, C., Forestier, L., Arrondel, C., Jacassier, D., Giatras, I., Drouot, L., Deschenes, G., Grunfeld, J.-P., Broyer, M., Gubler, M.-C., Antignac, C., Spectrum of mutations in the COL4A5 collagen gene in X-linked Alport syndrome. Am. J. Hum. Genet. 59 (1996), 1221–1232.
9. [9] Crockett, D.K., Pont-Kingdon, G., Gedge, F., Sumner, K., Seamons, R., Lyon, E., The Alprot syndrome COL4A5 variant database. Hum. Mutat. 31 (2010), E1652–E1657.
10. [10] Pieri, M., Stefenou, C., Zaravinos, A., Erguler, K., Stylianou, K., Lapathitis, G., Karaiskos, C., Savva, I., Paraskeva, R., Dweep, H., Sticht, C., Anastasiadou, N., Zouvani, I., Goumenos, D., Felekkis, K., Saleem, M., Voskarides, K., Gretz, N., Deltas, C., Evidence for the activation of unfolded protein response in collagen IV nephropathies. J. Am. Soc. Nephrol. 26 (2014), 260–275.
11. [11] Kleppel, M.M., Fan, W., Cheong, H.I., Michael, A.F., Evidence for separate networks of classical and novel basement membrane collagen. Characterization of alpha 3(IV)-Alport antigen heterodimer. J. Biol. Chem. 267 (1992), 4137–4142.
12. [12] Abrahamson, D., Hudson, B., Strogonova, L., Borza, D.B., St John, P.L., Cellular origins of type IV collagen networks in developing glomeruli. J. Am. Soc. Nephrol. 20 (2009), 1471–1479.
13. [13] Suh, J.H., Miner, J.H., The glomerular basement membrane as a barrier to albumin. Nat. Rev. Nephrol. 9 (2013), 470–477.
14. [14] Suleiman, H., Zang, L., Roth, R., Heuser, J.E., Miner, J.H., Shaw, A.S., Dani, A., Nanoscale protein architecture of the kidney glomerular basement membrane. Elife, 2, 2013, e01149.
15. [15] Staatz, W.D., Walsh, J.J., Pexton, T., Santoro, S.A., The alpha 2 beta 1 integrin cell surface collagen receptor binds to the alpha 1 (I)-CB3 peptide of collagen. J. Biol. Chem. 265 (1990), 4778–4781.
16. [16] Mohan, R.R., Mohan, R.R., Wilson, S.E., Discoidin domain receptor (DDR) 1 and 2: collagen-activated tyrosine kinase receptors in the cornea. Exp. Eye Res. 72 (2001), 87–92.
17. [17] Gross, O., Beirowski, B., Harvey, S.J., McFadden, C., Chen, D., Tam, S., Thorner, P.S., Smyth, N., Addicks, K., Bloch, W., Ninomiya, Y., Sado, Y., Weber, M., Vogel, W.F., DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. Kidney Int. 66 (2003), 102–111.
18. [18] Girgert, R., Martin, M., Kruegel, J., Miosge, N., Temme, J., Eckes, B., Muller, G.A., Gross, O., Integrin a2-deficient mice provide insights into the specific functions of collagen receptors in the kideney. Fibrogenesis Tissue Repair, 22, 2010 (1755–1536–3-19).
19. [19] Gross, O., Girgert, R., Beirowski, B., Kretzler, M., Kang, H.G., Kruegel, J., Miosge, N., Busse, A.C., Segerer, S., Vogel, W.F., Müller, G.A., Weber, M., Loss of collagen-receptor DDR1 delays renal fibrosis in hereditary type IV collagen disease. Matrix Biol. 29 (2010), 346–356.
20. [20] Rubel, D., Frese, J., Martin, M., Leibnitz, A., Girgert, R., Miosge, N., Eckes, B., Müller, G.A., Gross, O., Collagen receptors integrin alpha2beta1 and discoidin domain receptor 1 regulate maturation of the glomerular basement membrane and loss of integrin alpha2beta1 delays kidney fibrosis in COL4A3 knockout mice. Matrix Biol. 34 (2014), 13–21.
21. [21] Borza, C.M., Su, Y., Chen, X., Yu, L., Mont, S., Chetyrkin, S., Voziyan, P., Hudson, B.G., Billings, P.C., Jo, H., Bennett, J.S., Degrado, W.F., Eckes, B., Zent, R., Pozzi, A., Inhibition of integrin α2β1 ameliorates glomerular injury. J. Am. Soc. Nephrol. 23 (2012), 1027–1038.
22. [22] Barocas, V.H., Dorfman, K.D., Segal, Y., A model of strain-dependent glomerular basement membrane maintenance and its potential ramifications in health and disease. J. Biomech. Eng., 134, 2012, 081006.
23. [23] Kriz, W., Elger, M., Mundel, P., Lemley, K.V., Structure-stabilizing forces in the glomerular tuft. J. Am. Soc. Nephrol. 5 (1995), 1731–1739.
24. [24] Wyss, H.M., Henderson, J.M., Byfield, F.J., Bruggeman, L.A., Ding, Y., Huang, C., Suhn, J.H., Franke, T., Mele, E., Pollak, M.R., Miner, J.H., Janmey, P.A., Weitz, D.A., Miller, R.T., Biophysical properties of normal and diseased renal glomeruli. Am. J. Phys. Cell Physiol. 300 (2011), C397–C405.
25. [25] Meehan, D.T., Delimont, D., Cheung, L., Zallocchi, M., Sansom, S.C., Holzclaw, J.D., Rao, V., Cosgrove, D., Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease. Kidney Int. 76 (2009), 968–976.
26. [26] Gross, O., Beirowski, B., Koepke, M.L., Kuck, J., Reiner, M., Addicks, K., Smyth, N., Schulze-lohoff, E., Weber, M., Preemptive ramipril therapy delays renal failure and reduces fibrosis in COL4A3-knockout mice with Alport syndrome., 63, 2003, 438–446.
27. [27] Dufek, B., Meehan, D.T., Delimont, D., Linda Cheung, L., Gratton, M.A., Phillips, G., Song, W.-P., Liu, S., Cosgrove, D., Endothelin a receptor activation on mesangial cells initiates Alport glomerular disease. Kidney Int. 90 (2016), 300–310.
28. [28] Lammerding, J., Kazarov, A.R., Huang, H., Lee, R.T., Hemler, M.E., Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 7616–7621.
29. [29] Sachs, N., Sonnenberg, A., Cell-matrix adhesion of podocytes in physiology and disease. Nat. Rev. Nephrol. 9 (2013), 200–210.
30. [30] Kreidberg, J.A., Donovan, M.J., Goldstein, S.L., Rennke, H., Shepherd, K., Jones, R.C., Jaenisch, R., Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122 (1996), 3537–3547.
31. [31] Sachs, N., Kreft, M., van den Bergh Weerman, M.A., Beynon, A.J., Peters, T.A., Weening, J.J., Sonnenberg, A., Kidney failure in mice lacking the tetraspanin CD151. J. Cell Biol. 175 (2006), 33–39.
32. [32] Baleato, R.M., Guthrie, P.L., Gubler, M.C., Ashman, L.K., Roselli, S., Deletion of CD151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am. J. Pathol. 173 (2008), 927–937.
33. [33] Sachs, N., Claessen, N., Aten, J., Kreft, M., Teske, G.J., Koeman, A., Zuurbier, C.J., Janssen, H., Sonnenberg, A., Blood pressure influences end-stage renal disease of Cd151 knockout mice. J. Clin. Invest. 122 (2012), 348–358.
34. [34] Heidet, L., Gubler, M.C., The renal lesions of Alport syndrome. J. Am. Soc. Nephrol. 20 (2009), 1210–1215.
35. [35] Gross, O., Licht, C., Anders, H.J., Hoppe, B., Beck, B., Tönshoff, B., Höcker, B., Wygoda, S., Ehrich, J.H., Pape, L., Konrad, M., Rascher, W., Dötsch, J., Müller-Wiefel, D.E., Hoyer, P., Study Group Members of the Gesellschaft für Pädiatrische Nephrologie, Knebelmann, B., Pirson, Y., Grunfeld, J.P., Niaudet, P., Cochat, P., Heidet, L., Lebbah, S., Torra, R., Friede, T., Lange, K., Müller, G.A., Weber, M., Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int. 81 (2012), 494–501.
36. [36] Rüster, C., Wolf, G., Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 17 (2006), 2985–2991.
37. [37] Bae, E.H., Konvalinka, A., Fang, F., Zhou, X., Williams, V., Maksimowski, N., Song, X., Zhang, S.L., John, R., Oudit, G.Y., Pei, Y., Scholey, J.W., Characterization of the intrarenal renin-angiotensin system in experimental Alport syndrome. Am. J. Pathol. 185 (2015), 1423–1435.
38. [38] Cosgrove, D., Rodgers, K., Meehan, D., Miller, C., Bovard, K., Gilroy, A., Gardner, H., Kotelianski, V., Gotwals, P., Amatucci, A., Kalluri, R., Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am. J. Pathol. 157 (2000), 1649–1659.
39. [39] Kashtan, C.E., Kim, Y., Lees, G.E., Thorner, P.S., Virtanen, I., Miner, J.H., Abnormal glomerular basement membrane laminins in murine, canine, and human Alport syndrome: aberrant laminin alpha2 deposition is species independent. J. Am. Soc. Nephrol. 12 (2001), 252–260.
40. [40] Zallocchi, M., Johnson, B.M., Meehan, D.T., Delimont, D., Cosgrove, D., α1β1 integrin/Rac1-dependent mesangial invasion of glomerular capillaries in Alport syndrome. Am. J. Pathol. 183 (2013), 1269–1280.
41. [41] Chahdi, A., Miller, B., Sorokin, A., Endothelin 1 induces beta 1Pix translocation and Cdc42 activation via protein kinase A-dependent pathway. J. Biol. Chem. 280 (2005), 578–584.
42. [42] Krugmann, S., Jordens, I., Gevaert, K., Driessens, M., Vandekerckhove, J., Hall, A., Cdc42 induces filopodia by promoting the formation of an IRSp53:mena complex. Curr. Biol. 11 (2001), 1645–1655.
43. [43] Takahashi, H., Sekino, Y., Tanaka, S., Mizui, T., Kishi, S., Shirao, T., Drebrin-dependent actin clustering in dendritic filopodia governs synaptic targeting of postsynaptic density-95 and dendritic spine morphogenesis. J. Neurosci. 23 (2003), 6586–6595.
44. [44] Delimont, D., Dufek, B.M., Meehan, D.T., Zallocchi, M., Gratton, M.A., Phillips, G., Cosgrove, D., Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS One, 9, 2014, e99083.
45. [45] Fukuda, R., Suico, M.A., Kai, Y., Omachi, K., Motomura, K., Koga, T., Komohara, Y., Koyama, K., Yokota, T., Taura, M., Shuto, T., Kai, H., Podocyte p53 limits the severity of experimental Alport syndrome. J. Am. Soc. Nephrol. 27 (2016), 144–157.
46. [46] Murphy, S.H., Suzuki, K., Downes, M., Welch, G.L., De Jesus, P., Miraglia, L.J., Orth, A.P., Chanda, S.K., Evans, R.M., Verma, I.M., Tumor suppressor protein (p)53, is a regulator of NF-ĸB repression by the glucocorticoid receptor. PNAS 108 (2011), 17117–17122.
47. [47] Sayers, R., Kalluri, R., Rodgers, K.D., Shield, C.F. III, Meehan, D.T., Cosgrove, D., Role for transforming growth factor-β1 in Alport renal disease progression. Kidney Int. 56 (1999), 1662–1673.
48. rd, Werb, Z., Kalluri, R., Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med., 3, 2006, e100.
49. [49] Rao, V.H., Meehan, D.T., Delimont, D., Nakajima, M., Wada, T., Gratton, M.A., Cosgrove, D., Role for macrophage metalloelastase in glomerular basement membrane damage associated with Alport syndrome. Am. J. Pathol. 169 (2006), 32–46.
50. [50] Andrews, K.L., Betsuyaku, T., Rogers, S., Shipley, J.M., Senior, R.M., Miner, J.H., Gelatinase B (MMP-9) is not essential in the normal kidney and does not influence progression of renal disease in a mouse model of Alport syndrome. Am. J. Pathol. 157 (2000), 303–311.
51. [51] Kalluri, R., Shield, C.F., Todd, P., Hudson, B.G., Neilson, E.G., Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis. J. Clin. Invest. 99 (1997), 2470–2478.
52. [52] Abrahamson, D.R., Isom, K., Roach, E., Stroganova, L., Zelenchuk, A., Miner, J.H., St. John, P.L., Laminin compensation in collagen alpha3(IV) knockout (Alport) glomeruli contributes to permeability defects. J. Am. Soc. Nephrol. 18 (2007), 2465–2472.
53. [53] Tanaka, M., Asada, M., Higashi, A.Y., Nakamura, J., Oguchi, A., Tomita, M., Yamada, S., Asada, N., Takase, M., Okuda, T., Kawachi, H., Economides, A.N., Robertson, E., Takahashi, S., Sakurai, T., Goldschmeding, R., Muso, E., Fukatsu, A., Kita, T., Yanagita, M., Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J. Clin. Invest. 120 (2010), 768–777.
54. [54] Abbate, M., Zoja, C., Remuzzi, G., How does proteinuria cause progressive renal damage?. J. Am. Soc. Nephrol. 17 (2006), 2974–2984.
55. [55] Jarad, G., Knutsen, R.H., Mecham, R.P., Miner, J.H., Albumin contributes to kidney disease in Alport syndrome. Am. J. Phys. Renal Phys. 311 (2016), F120–F130.
56. [56] Hahm, K., Lukashev, M.E., Luo, Y., Yang, W.J., Dolinski, B.M., Weinreb, P.H., Simon, K.J., Chun Wang, L., Leone, D.R., Lobb, R.R., McCrann, D.J., Allaire, N.E., Horan, G.S., Fogo, A., Kalluri, R., Shield, C.F. III, Sheppard, D., Gardner, H.A., Violette, S.M., Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am. J. Pathol. 170 (2007), 110–125.
57. [57] Gomez, L.G., MacKenna, D.A., Johnson, B.G., Kaimal, V., Roach, A.M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., Xia, T.H., Liu, X., Borza, D.B., Grafals, M., Shankland, S.J., Himmelfarb, J., Portilla, D., Liu, S., Chau, B.N., Duffield, J.S., Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125 (2015), 141–156.
58. [58] Rodgers, K.D., Rao, V., Meehan, D.T., Fager, N., Gotwals, P., Ryan, S.T., Koteliansky, V., Nemori, R., Cosgrove, D., Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int. 63 (2003), 1338–1355.
59. [59] Kim, M., Piaia, A., Shenoy, N., Kagan, D., Gapp, B., Kueng, B., Weber, D., Dietrich, W., Ksiazek, I., Progression of Alport kidney disease in Col4a3 knock out mice is independent of sex or macrophage depletion by clodronate treatment. PLoS One, 10, 2015, e0141231.
60. [60] Dennis, J., Meehan, D.T., Delimont, D., Zallocchi, M., Perry, G.A., O'Brien, S., Tu, H., Pihlajaniemi, T., Cosgrove, D., Collagen XIII induced in vascular endothelium mediates alpha1beta1 integrin-dependent transmigration of monocytes in renal fibrosis. Am. J. Pathol. 177 (2010), 2527–2540.
61. [61] Lebleu, V.S., Sugimoto, H., Miller, C.A., Gattone, V.H. II, Kalluri, R., Lymphocytes are dispensable for glomerulonephritis but required for renal interstitial fibrosis in matrix defect-induced Alport renal disease. Lab. Investig. 88 (2008), 284–292.
62. [62] Heikkila, P., Parpala, T., Lukkarinen, O., Weber, M., Tryggvason, K., Adenovirus-mediated gene transfer into kidney glomeruli using an ex vivo and in vivo kidney perfusion system – first steps towards gene therapy of Alport syndrome. Gene Ther. 3 (1996), 21–27.
63. [63] Heikkilä, P., Tibell, A., Morita, T., Chen, Y., Wu, G., Sado, Y., Ninomiya, Y., Pettersson, E., Tryggvason, K., Adenovirus-mediated transfer of type IV collagen alpha5 chain cDNA into swine kidney in vivo: deposition of the protein into the glomerular basement membrane. Gene Ther. 8 (2001), 882–890.
64. [64] Heidet, L., Borza, D.B., Jouin, M., Sich, M., Mattei, M.G., Sado, Y., Hudson, B.G., Hastie, N., Antignac, C., Gubler, M.C., A human-mouse chimera of the alpha3alpha4alpha5(IV) collagen protomer rescues the renal phenotype in Col4a3 −/− Alport mice. Am. J. Pathol. 163 (2003), 1633–1644.
65. [65] Lin, X., Suh, J.H., Go, G., Miner, J.H., Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J. Am. Soc. Nephrol. 25 (2014), 687–692.
66. [66] Sugimoto, H., Mundel, T.M., Sund, M., Xie, L., Cosgrove, D., Kalluri, R., Bone marrow derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 7321–7326.
67. [67] Ninichuk, V., Gross, O., Segerer, S., Hoffmann, R., Radomska, E., Buchstaller, A., Huss, R., Akis, N., Schlöndorff, D., Anders, H.J., Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 70 (2006), 121–129.
68. [68] Sedrakyan, S., Da Sacco, S., Milanesi, A., Shiri, L., Petrosyan, A., Varimezova, R., Warburton, D., Lemley, K.V., De Filippo, R.E., Perin, L., Injection of amniotic fluid stem cells delays progression of renal fibrosis. J. Am. Soc. Nephrol. 23 (2012), 661–673.
69. [69] LeBleu, V., Sugimoto, H., Mundel, T.M., Gerami-Naini, B., Finan, E., Miller, C.A., Gattone, V.H. II, Lu, L., Shield, C.F. III, Folkman, J., Kalluri, R., Stem cell therapies benefit Alport syndrome. J. Am. Soc. Nephrol. 20 (2009), 2359–2370.
70. [70] Jais, J.P., Knebelmann, B., Giatras, I., DeMarchi, M., Rizzoni, G., Reneiri, A., Weber, M., Gross, O., Netzer, K.O., Flinter, F., Pirson, Y., Verellen, C., Wieslan der, J., Persson, U., Tryggvason, K., Martin, P., Hettz, J.M., Schroder, C., Sanak, M., Krejcova, S., Carvalho, M.F., Saus, J., Antignac, C., Smeets, H., Gubler, M.C., X-linked Alport syndrome: natural history of 195 families and genotype-phenotype correlations in males. J. Am. Soc. Nephrol. 11 (2000), 649–657.